AIMS Biophysics, 2017, 4(1): 33-42. doi: 10.3934/biophy.2017.1.33

Research article

Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Bilayer degradation in reactive environments

Department of Chemical and Biological Engineering, Drexel University, 3101 Chestnut St, Philadelphia PA 19104, USA

Lipid vesicles, or liposomes have been widely studied both as a model for cell membranes and for applications such as drug delivery. As a rule, their aqueous environment (in vitro or in vivo) contains various degradation agents, ranging from free radicals to acids and enzymes. This paper investigates the degradation of lipid vesicles as a function of environmental conditions using 3d Monte-Carlo simulations. The time-scale for bilayer degradation is found to be independent of the liposome size, but highly sensitive to the concentration of degradation molecules in solution and to the rate of the degradation reaction.
  Figure/Table
  Supplementary
  Article Metrics

References

1. Bruggemann D, Frohnmayer JP, Spatz JP (2014) Model systems for studying cell adhesion and biomimetic actin networks. Beilstein J of Nanotec 5: 1193–1202.    

2. Wu F, Tan CM (2014) The engineering of artificial cellular nanosystems using synthetic biology approaches. Wiley Int Rev-Nanomed & Nanobiotech 6: 369–383.

3. Chang HI, Yeh MK (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 7: 49–60.

4. Gyorgy B, Hung ME, Breakefield XO, et al. (2015) Therapeutic applications of extracellular vesicles: clinical promise and open questions, In: Insel PA, editor, Annual Review of Pharmacology and Toxicology, 439–464.

5. Lombardo D, Calandra P, Barreca D, et al. (2016) Soft interaction in liposome nanocarriers for therapeutic drug delivery. Nanomaterials 6.

6. Anderson JM, Shive MS (2012) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Del Rev 64: 72–82.    

7. Davis KA, Anseth KS (2002) Controlled release from crosslinked degradable networks. Crit Rev Ther Drug 19: 385–423.

8. Herrero-Vanrell R, Refojo MF (2001) Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Del Rev 52: 5–16.    

9. Andresen TL, Jensen SS, Jorgensen K (2005) Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog Lipid Res 44: 68–97.    

10. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Delivery Rev 65: 36–48.    

11. Guo X, Szoka FC (2003) Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Accts Chem Res 36: 335–341.    

12. Balaure PC, Grumezescu AM (2015) Smart synthetic polymer nanocarriers for controlled and site-specific drug delivery. Curr Topics Med Chem 15: 1424–1490.    

13. Mellal D, Zumbuehl A (2014) Exit-strategies—smart ways to release phospholipid vesicle cargo. J Mat Chem B 2: 247–252.    

14. Felber AE, Dufresne MH, Leroux JC (2012) pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv Drug Del Rev 64: 979–992.    

15. Fleige E, Quadir MA, Haag R (2012) Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: Concepts and applications. Adv Drug Del Rev 64: 866–884.    

16. Paliwal SR, Paliwal R, Vyas SP (2015) A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery. Drug Del 22: 231–242.    

17. Hwang JY, Li ZB, Loh XJ (2016) Small molecule therapeutic-loaded liposomes as therapeutic carriers: from development to clinical applications. Rsc Adv 6: 70592–70615.    

18. Karimi M, Ghasemi A, Zangabad PS, et al. (2016) Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev 45: 1457–1501.    

19. Siepmann J, Siepmann F (2008) Mathematical modeling of drug delivery. I J Pharma 364: 328–343.

20. Siepmann J, Siepmann F (2012) Modeling of diffusion controlled drug delivery. J Cont Rel 161: 351–362.    

21. Siepmann J, Peppas NA (2011) Higuchi equation: Derivation, applications, use and misuse. I J Pharma 418: 6–12.

22. Siepmann J, Gopferich A (2001) Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Del Rev 48: 229–247.    

23. Peppas NA, Narasimhan B (2014) Mathematical models in drug delivery: How modeling has shaped the way we design new drug delivery systems. J Cont Rel 190: 75–81.    

24. Dan N (2015) Compound release from core-shell carriers triggered by oscillating fields: Monte Carlo simulations. Coll & and Surf A 481: 80–86.

25. Dan N (2016) Compound release from nanostructured lipid carriers (NLCs). J Food Eng 171: 37–43.    

26. Dan N (2014) Nanostructured lipid carriers: effect of solid phase fraction and distribution on the release of encapsulated materials. Langmuir 30: 13809–13814.    

27. Duncan GA, Bevan MA (2015) Computational design of nanoparticle drug delivery systems for selective targeting. Nanoscale 7: 15332–15340.    

28. Biswas S, Mani E, Mondal A, et al. (2016) Supramolecular polyelectrolyte complex (SPEC): pH dependent phase transition and exploitation of its carrier properties. Soft Mat 12: 1989–1997.    

29. Eavarone DA, Soundararajan V, Haller T, et al. (2010) A voxel-based Monte Carlo model of drug release from bulk eroding nanoparticles. J Nanosci & Nanotech 10: 5903–5907.

30. Landau DP, Binder K (2014) A guide to Monte Carlo simulations in statistical physics, Cambridge University Press.

31. Nelson P (2013) Biological Physics: Freeman.

32. Dan N (2015) Drug release through liposome pores. Coll & Surf B 126: 80–86.

33. Dan N (2016) Environmentally-induced degradation of solid-lipid nanoparticles. Bioint Res-Appl Chem 6: 1464–1468.

34. Parmentier J, Thomas N, Mullertz A, et al. (2012) Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis. I J Pharma 437: 253–263.

35. Parmentier J, Thewes B, Gropp F, et al. (2011) Oral peptide delivery by tetraether lipid liposomes. I J Pharma 415: 150–157.

36. Jensen SM, Christensen CJ, Petersen JM, et al. (2015) Liposomes containing lipids from Sulfolobus islandicus withstand intestinal bile salts: An approach for oral drug delivery? I J Pharma 493: 63–69.

37. Zhang B, Xue AY, Zhang C, et al. (2016) Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel. Pharmazie 71: 320–326.

38. Allen TM, Everest JM (1983) Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drugs in rats. J of Pharma and Exp Therapeutics 226: 539–544.

39. Lasic DD, Needham D (1995) The “Stealth” liposome: A prototypical biomaterial. Chem Rev 95: 2601–2628.    

Copyright Info: © 2017, Nily Dan, licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Article outline

Show full outline
Copyright © AIMS Press All Rights Reserved